NCT04807478View on ClinicalTrials.gov

Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

April 1, 2022

Primary Completion Date

May 1, 2028

Study Completion Date

May 1, 2029

Conditions
Parenteral Nutrition Associated Liver DiseaseEssential Fatty Acid DeficiencyNeurocognitive DeficitMalnutritionPediatric ALL
Interventions
DRUG

Omegaven® (fish oil triglycerides) Injectable Emulsion

Dose, frequency and duration is a decision of the Investigator

Sponsors

Lead Sponsor

Fresenius Kabi
All Listed Sponsors
lead

Fresenius Kabi

INDUSTRY